Compounds and methods for CD73 modulation and indications therefor

1. A compound having Formula I:

or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:

A is a 5-6 membered aromatic ring or a 4-7 membered nitrogen containing heterocycloalkyl, wherein A is substituted with 0-3 R 4 , provided that when ring A is a 4-7 membered nitrogen containing heterocycloalkyl, then the pyridazinone moiety of Formula I is attached to a nitrogen atom of A;

E is phenyl or a 5 or 6 membered heteroaryl, wherein E is substituted with 0-3 Q and 0-1 R 11 , provided that when E is a 5 or 6 membered heteroaryl, O is not attached to a heteroatom of E;

L is absent, —C(O)N(H)—, C 0 -C 3 alkylene, —N(H)—, or —O—;

G is one of the following groups:

(a) cycloalkyl substituted with 0-4 T 1 and 0-1 T 2 ;

(b) cycloalkenyl substituted with 0-4 T 1 and 0-1 T 2 ;

(c) a bridged carbocylic ring substituted with 0-4 T 1 and 0-1 T 2 ;

(d) a carbocyclic spiro ring containing two cycloalkyl groups joined by one common spiro carbon atom, wherein the carbocyclic spiro ring is substituted with 0-4 T 1 and 0-1 T 2 ;

(e) a heterocyclic spiro ring containing two cyclic groups with at least one heteroatom, wherein the two cyclic groups are joined by one common spiro carbon atom, wherein the heterocyclic spiro ring is substituted with 0-3 T 5 , 0-1 T 6 ;

(f) phenyl substituted with 0-4 T 1 and 0-1 T 4 ;

(g) heterocycloalkyl substituted with 0-4 T 5 and 0-1 T 6 ;

(h) heterocycloalkenyl substituted with 0-4 T 5 and 0-1 T 6 ;

(i) a bridged heterocylic ring substituted with 0-4 T 5 and 0-1 T 6 ; or

(j) heteroaryl substituted with 0-3 T 5 and 0-1 T 3 ;

each Q is independently halogen, CN, or alkyl optionally substituted with 1-3 halogens;

each T 1 is independently halogen, hydroxyl, alkyl optionally substituted with 1-3 R b , alkenyl optionally substituted with 1-3 R b , alkynyl optionally substituted with 1-3 R b , CN, cyanoalkyl, alkoxyl optionally substituted with 1-3 R b , or alkoxyalkyl optionally substituted with 1-3 R b ;

T 2 is —(CH 2 ) 0-3 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-3 —SO 2 —R 7 , —(CH 2 ) 0-3 —SO 2 N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )SO 2 N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )C(O)N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )C(O)R 8 , —(CH 2 ) 0-3 —N(R 9 )C(O)OR 9 , —(CH 2 ) 0-3 —N(R 9 )R 9 , —(CH 2 ) 0-3 —C(O)N(R 9 )R 9 , —(CH 2 ) 0-3 —C(O)OR 9 , —(CH 2 ) 0-3 —C(O)R 10 , —(CH 2 ) 0-3 —C(O)H, —(CH 2 ) 0-3 —N(R 9 )C(O)R 10 , —(CH 2 ) 0-3 cycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-3 -phenyl optionally substituted with 1-3 Z 5 , or —(CH 2 ) 0-3 heteroaryl optionally substituted with 1-3 Z 5 ;

T 3 is —(CH 2 ) 0-3 —C(O)N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )R 9 , —(CH 2 ) 0-3 —C(O)OR 9 , —(CH 2 ) 0-3 -cycloalkyl, —(CH 2 ) 0-3 -cycloalkenyl, —(CH 2 ) 0-3 -heterocycloalkyl, —(CH 2 ) 0-3 -heterocycloalkenyl, —O-heterocycloalkyl optionally substituted with 4-chloropyridazin-3-one-5-yl, or —(CH 2 ) 0-3 -bridged carbocyclic ring, wherein the —(CH 2 ) 0-3 -cycloalkyl, —(CH 2 ) 0-3 -cycloalkenyl, —(CH 2 ) 0-3 -heterocycloalkyl, —(CH 2 ) 0-3 -heterocycloalkenyl, or —(CH 2 ) 0-3 -bridged carbocyclic are each optionally substituted with 1-3 Z 5 and 0-1 Z 1 , provided that when T 3 is attached to a heteroatom of G, G cannot be attached to an oxygen or nitrogen atom of T 3 ;

T 4 is —(CH 2 ) 0-3 C(O)OR 9 , —(CH 2 ) 0-3 —N(R 9 )C(O)R 9 , —(CH 2 ) 0-3 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-3 —SO 2 —R 7 , —(CH 2 ) 0-3 —SO 2 N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )C(O)N(R′)R 9 , or N(R a ) 2 ;

each T 5 is independently halogen, hydroxyl, alkyl optionally substituted with 1-3 R b , alkenyl optionally substituted with 1-3 R b , alkynyl optionally substituted with 1-3 R b , CN, cyanoalkyl, alkoxyl optionally substituted with 1-3 R b , or alkoxyalkyl optionally substituted with 1-3 R b , provided that when T 5 is attached to a heteroatom of G, T 5 cannot be halogen, hydroxyl, CN, or alkoxyl optionally substituted with 1-3 R b ;

T 6 is —(CH 2 ) 0-3 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-3 —SO 2 —R 7 , —(CH 2 ) 0-3 —SO 2 N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )SO 2 N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )C(O)N(R 9 )R 9 , —(CH 2 ) 0-3 —N(R 9 )C(O)R 9 , —(CH 2 ) 0-3 —N(R 9 )C(O)OR 9 , —(CH 2 ) 0-3 —N(R 8 )R 9 , —(CH 2 ) 0-3 —C(O)—N(R 8 )R 9 , —(CH 2 ) 0-3 —C(O)OR 9 , —(CH 2 ) 0-3 —C(O)R 10 , —(CH 2 ) 0-3 —N(R 9 )C(O)R 10 , —N(H)C(H)C═O, —(CH 2 ) 0-3 cycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-2 heterocycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-3 heteroaryl optionally substituted with 1-3 Z 5 , or 4-chloropyridazin-3-one-5-yl, provided that when T 6 is attached to a heteroatom of G, G cannot be attached to an oxygen or nitrogen atom of T 6 ;

R a is H or alkyl;

R b is halogen, CN, CF 3 , or hydroxyl, provided that not more than 1 R b can be CF 3 ;

R 1 is C 1 -C 4 alkoxyC 1 -C 4 alkyl, C 2 -C 4 alkenyl substituted with 1-3 Z 2 , or C 2 -C 4 alkyl substituted with 1-3 Z 2 ;

R 2 is H, halogen, alkyl, alkenyl, alkoxyl, haloalkyl, CF 3 , or CN;

R 3 is H, halogen, alkyl, CN, or haloalkyl;

each R 4 is independently halogen, CN, or alkyl optionally substituted with 1-3 halogens;

R 7 is alkyl optionally substituted with 1-4 Z 4 , —C 0 -C 3 alkyl-cycloalkyl optionally substituted with 1-4 Z 3 , —C 0 -C 3 alkyl-phenyl optionally substituted with 1-4 Z 3 , —C 0 -C 3 alkyl-heteroaryl optionally substituted with 1-3 Z 5 , or —C 0 -C 3 alkyl-heterocycloalkyl optionally substituted with 1-3 Z 5 ;

R 8 is H, alkyl optionally substituted with 1-4 Z 4 , alkenyl optionally substituted with 1-4 Z 4 , —C 0 -C 3 alkyl-cycloalkyl optionally substituted with 1-4 Z 3 , —C 0 -C 3 alkyl-phenyl optionally substituted with 1-4 Z 3 , —C 0 -C 3 alkyl-heteroaryl optionally substituted with 1-3 Z 5 , —C 0 -C 3 alkyl-heterocycloalkyl optionally substituted with 1-3 Z 5 , or a bridged carbocylic ring substituted with 0-5 T 1 ;

each R 9 is independently H or alkyl optionally substituted with 1-4 Z 4 ;

R 10 is alkyl substituted with 0-4 Z 4 , —C 0 -C 3 alkyl-cycloalkyl optionally substituted with 1-4 Z 3 , —C 0 -C 3 alkyl-phenyl optionally substituted with 1-4 Z 3 , —C 0 -C 3 alkyl-heteroaryl optionally substituted with 1-3 Z 5 , or —C 0 -C 3 alkyl-heterocycloalkyl optionally substituted with 1-3 Z 5 ;

R 11 is NH 2 ;

Z 1 is cyanoalkyl, —(CH 2 ) 0-2 —C(O)OR 9 , —(CH 2 ) 0-2 —C(O)—N(R 8 )R 9 , provided that when Z 1 is attached to a heteroatom, then Z 1 is not C(O)OR 9 ;

each Z 2 is independently hydroxyl, halogen, NH 2 , or CN, provided that not more than 1 Z 2 can be NH 2 ;

each Z 3 is independently alkyl, halogen, haloalkyl, hydroxyl, hydroxyalkyl, alkoxyl, alkoxyalkyl, or CN;

each Z 4 is independently hydroxyl, halogen, alkoxyl, or CN; and

each Z 5 is independently alkyl, haloalkyl, hydroxyl, hydroxyalkyl, halogen, alkoxyl, alkoxyalkyl, CN, or cyanoalkyl, provided that when Z 5 is attached to a heteroatom, then Z 5 is not halogen, hydroxyl, alkoxyl, or CN.

2. The compound according to claim 1 , wherein ring A is azetidine, pyrrolidine, piperidine, imidazole, thiazole, or pyrazolyl.

3. The compound according to claim 1 having Formula II:

or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein L is absent, —N(H)—, or —O—; and m is 0-2.

4. The compound according to claim 1 having Formula IIIa or IIIb:

or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof, wherein:

E is phenyl or a 6 membered heteroaryl, wherein E is substituted with 0-2 Q, provided that when E is a 6 membered heteroaryl, O is not attached to a heteroatom of E;

G is one of the following groups:

(a) C 3 -C 6 cycloalkyl substituted with 0-3 T 1 and 0-1 T 2 ;

(b) C 3 -C 6 cycloalkenyl substituted with 0-3 T 1 and 0-1 T 2 ;

(c) a 5-9 membered bridged carbocylic ring substituted with 0-3 T 1 and 0-1 T 2 ;

(d) a 5-9 membered carbocyclic spiro ring containing two cycloalkyl groups joined by one common spiro carbon atom, wherein the carbocyclic spiro ring is substituted with 0-3 T 1 and 0-1 T 2 ;

(e) a 6-9 membered heterocyclic spiro ring containing two cyclic groups with at least one heteroatom, wherein the two cyclic groups are joined by one common spiro carbon atom, wherein the heterocyclic spiro ring is substituted with 0-3 T 5 , 0-1 T 6 ;

(f) phenyl substituted with 0-3 T 1 and 0-1 T 4 ;

(g) a 4-6 membered heterocycloalkyl substituted with 0-3 T 5 and 0-1 T 6 ;

(h) a 4-6 membered heterocycloalkenyl substituted with 0-3 T 5 and 0-1 T 6 ;

(i) a 5-9 membered bridged heterocylic ring substituted with 0-3 T 5 and 0-1 T 6 ; or

(j) a 5-6 membered heteroaryl substituted with 0-3 T 5 and 0-1 T 3 ;

each Q is independently halogen, CN, or C 1 -C 3 alkyl optionally substituted with 1-3 halogens;

each T 1 is independently halogen, hydroxyl, C 1 -C 6 alkyl optionally substituted with 1-3 R b , C 2 -C 5 alkenyl optionally substituted with 1-3 R b , C 2 -C 5 alkynyl optionally substituted with 1-3 R b , CN, C 1 -C 6 cyanoalkyl, C 1 -C 6 alkoxyl optionally substituted with 1-3 R b , or C 1 -C 6 alkoxyC 1 -C 6 alkyl optionally substituted with 1-3 R b ;

T 2 is —(CH 2 ) 0-2 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-2 —SO 2 —R 7 , —(CH 2 ) 0-2 —SO 2 N(R′)R 9 , —(CH 2 ) 0-2 —N(R 9 )SO 2 N(R′)R 9 , —(CH 2 ) 0-2 —N(R 9 )C(O)N(R 9 )R 9 , —(CH 2 ) 0-2 —N(R 9 )C(O)R 8 , —(CH 2 ) 0-2 —N(R 9 )C(O)OR 9 , —(CH 2 ) 0-2 —N(R′)R 9 , —(CH 2 ) 0-2 —C(O)N(R′)R 9 , —(CH 2 ) 0-2 —C(O)OR 9 , —(CH 2 ) 0-2 —C(O)R 10 , —(CH 2 ) 0-2 —C(O)H, —(CH 2 ) 0-2 —N(R 9 )C(O)R 10 , —(CH 2 ) 0-2 C 3 -C 6 cycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-2 -phenyl optionally substituted with 1-3 Z 5 , or —(CH 2 ) 0-2 -5-6 membered heteroaryl optionally substituted with 1-3 Z 5 ;

T 3 is —(CH 2 ) 0-2 —C(O)N(R′)R 9 , —(CH 2 ) 0-2 —N(R′)R 9 , —(CH 2 ) 0-2 —C(O)OR 9 , —(CH 2 ) 0-2 —C 3 -C 6 cycloalkyl, —(CH 2 ) 0-2 -5-6 membered heterocycloalkyl, —O-5-6 membered heterocycloalkyl optionally substituted with 4-chloropyridazin-3-one-5-yl, or —(CH 2 ) 0-2 -5-9 membered bridged carbocyclic ring, wherein the —(CH 2 ) 0-2 —C 3 -C 6 cycloalkyl, —(CH 2 ) 0-2 -5-6 membered heterocycloalkyl, or —(CH 2 ) 0-2 -5-9 membered bridged carbocyclic are each optionally substituted with 1-3 Z 5 and 0-1 Z 1 , provided that when T 3 is attached to a heteroatom of G, G cannot be attached to an oxygen or nitrogen atom of T 3 ;

T 4 is —(CH 2 ) 0-2 C(O)OR 9 , —(CH 2 ) 0-2 —N(R 9 )C(O)R 8 , —(CH 2 ) 0-2 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-2 —SO 2 —R 7 , —(CH 2 ) 0-2 —SO 2 N(R′)R 9 , —(CH 2 ) 0-2 —N(R 9 )C(O)N(R′)R 9 , or N(R a ) 2 ;

each T 5 is independently halogen, hydroxyl, C 1 -C 6 alkyl optionally substituted with 1-3 R b , C 2 -C 6 alkenyl optionally substituted with 1-3 R b , C 2 -C 6 alkynyl optionally substituted with 1-3 R b , CN, C 1 -C 6 cyanoalkyl, C 1 -C 6 alkoxyl optionally substituted with 1-3 R b , or C 1 -C 6 alkoxyC 1 -C 6 alkyl optionally substituted with 1-3 R b , provided that when T 5 is attached to a heteroatom of G, T 5 cannot be halogen, hydroxyl, CN, or C 1 -C 6 alkoxyl optionally substituted with 1-3 R b ;

T 6 is —(CH 2 ) 0-2 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-2 —SO 2 —R 7 , —(CH 2 ) 0-2 —SO 2 N(R 9 )R 9 , —(CH 2 ) 0-2 —N(R 9 )SO 2 N(R′)R 9 , —(CH 2 ) 0-2 —N(R 9 )C(O)N(R′)R 9 , —(CH 2 ) 0-2 —N(R 9 )C(O)R 8 , —(CH 2 ) 0-2 —N(R 9 )C(O)OR 9 , —(CH 2 ) 0-2 —N(R 9 )R 9 , —(CH 2 ) 0-2 —C(O)—N(R′)R 9 , —(CH 2 ) 0-2 —C(O)OR 9 , —(CH 2 ) 0-2 —C(O)R 10 , —(CH 2 ) 0-2 —N(R 9 )C(O)R 10 , —N(H)C(H)C═O, —(CH 2 ) 0-2 —C 3 -C 6 cycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-2 -5-6 membered heterocycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-3 -5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , or 4-chloropyridazin-3-one-5-yl, provided that when T 6 is attached to a heteroatom of G, G cannot be attached to an oxygen or nitrogen atom of T 6 ;

R a is H or C 1 -C 6 alkyl;

R b is halogen, CN, CF 3 , or hydroxyl, provided that not more than 1 R b can be CF 3 ;

R 2 is H, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 1 -C 6 alkoxyl, C 1 -C 6 haloalkyl, CF 3 , or CN;

R 3 is H, halogen, C 1 -C 6 alkyl, CN, or C 1 -C 6 haloalkyl;

each R 4 is independently halogen, CN, or C 1 -C 3 alkyl optionally substituted with 1-3 halogens;

R 7 is C 1 -C 6 alkyl optionally substituted with 1-4 Z 4 , —C 0 -C 2 alkyl-C 3 -C 6 cycloalkyl optionally substituted with 1-4 Z 3 , —C 0 -C 2 alkyl-phenyl optionally substituted with 1-4 Z 3 , —C 0 -C 2 alkyl-5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , or —C 0 -C 2 alkyl-5-6 membered heterocycloalkyl optionally substituted with 1-3 Z 5 ;

R 8 is H, C 1 -C 6 alkyl optionally substituted with 1-4 Z 4 , C 2 -C 6 alkenyl optionally substituted with 1-4 Z 4 , —C 0 -C 2 alkyl-C 3 -C 6 cycloalkyl optionally substituted with 1-4 Z 3 , —C 0 -C 2 alkyl-phenyl optionally substituted with 1-4 Z 3 , —C 0 -C 2 alkyl-5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , —C 0 -C 2 alkyl-5-6 membered heterocycloalkyl optionally substituted with 1-3 Z 5 , or a 5-9 membered bridged carbocylic ring substituted with 0-4 Ti;

each R 9 is independently H or C 1 -C 6 alkyl optionally substituted with 1-4 Z 4 ;

R 10 is C 1 -C 6 alkyl substituted with 0-4 Z 4 , —C 0 -C 2 alkyl-C 3 -C 6 cycloalkyl optionally substituted with 1-4 Z 3 , —C 0 -C 2 alkyl-phenyl optionally substituted with 1-4 Z 3 , —C 0 -C 2 alkyl-5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , or —C 0 -C 2 alkyl-5-6 membered heterocycloalkyl optionally substituted with 1-3 Z 5 ;

R 11 is NH 2 ;

Z 1 is C 1 -C 6 cyanoalkyl, —(CH 2 ) 0-2 —C(O)OR 9 , —(CH 2 ) 0-2 —C(O)—N(R 8 )R 9 , provided that when Z 1 is attached to a heteroatom, then Z 1 is not —C(O)OR 9 ;

each Z 2 is independently hydroxyl, halogen, CN;

each Z 3 is independently C 1 -C 6 alkyl, halogen, C 1 -C 6 haloalkyl, hydroxyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 alkoxyl, or CN;

each Z 4 is independently, hydroxyl, halogen, C 1 -C 6 alkoxyl, or CN; and

each Z 5 is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, hydroxyl, C 1 -C 6 hydroxyalkyl, halogen, C 1 -C 6 alkoxyl, CN, or C 1 -C 6 cyanoalkyl, provided that when Z 5 is attached to a heteroatom, then Z 5 is not halogen, hydroxyl, C 1 -C 6 alkoxyl, or CN.

5. The compound according claim 1 , wherein:

E is phenyl or a 6 membered heteroaryl, wherein E is substituted with 0-1 Q, provided that when E is a 6 membered heteroaryl, O is not attached to a heteroatom of E;

G is one of the following groups:

(a) C 3 -C 6 cycloalkyl substituted with 0-2 T 1 and 0-1 T 2 ;

(b) C 3 -C 6 cycloalkenyl substituted with 0-2 T 1 and 0-1 T 2 ;

(c) a 5-9 membered bridged carbocylic ring substituted with 0-2 T 1 and 0-1 T 2 ;

(d) a 5-9 membered carbocyclic spiro ring containing two cycloalkyl groups joined by one common spiro carbon atom, wherein the carbocyclic spiro ring is substituted with 0-2 T 1 and 0-1 T 2 ;

(e) a 6-9 membered heterocyclic spiro ring containing two cyclic groups with at least one heteroatom, wherein the two cyclic groups are joined by one common spiro carbon atom, wherein the heterocyclic spiro ring is substituted with 0-2 T 5 , 0-1 T 6 ;

(f) phenyl substituted with 0-2 T 1 and 0-1 T 4 ;

(g) a 4-6 membered heterocycloalkyl substituted with 0-2 T 5 and 0-1 T 6 ;

(h) a 4-6 membered heterocycloalkenyl substituted with 0-2 T 5 and 0-1 T 6 ;

(i) a 5-9 membered bridged heterocylic ring substituted with 0-2 T 5 and 0-1 T 6 ; or

(j) a 5-6 membered heteroaryl substituted with 0-2 T 5 and 0-1 T 3 ;

Q is independently halogen, CN, or C 1 -C 4 alkyl optionally substituted with 1-3 halogens;

each T 1 is independently halogen, hydroxyl, C 1 -C 4 alkyl optionally substituted with 1-3 R b , C 2 -C 4 alkenyl optionally substituted with 1-3 R b , C 2 -C 4 alkynyl optionally substituted with 1-3 R b , CN, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkoxyl optionally substituted with 1-3 R b , or C 1 -C 4 alkoxyC 1 -C 4 alkyl optionally substituted with 1-3 R b ;

T 2 is —(CH 2 ) 0-1 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-1 —SO 2 —R 7 , —(CH 2 ) 0-1 —SO 2 N(R 8 )R 9 , —(CH 2 ) 0-1 —N(R 9 )SO 2 N(R 9 )R 9 , —(CH 2 ) 0-1 —N(R 9 )C(O)N(R 8 )R 9 , —(CH 2 ) 0-1 —N(R 9 )C(O)R 8 , —(CH 2 ) 0-1 —N(R 9 )C(O)OR 9 , —(CH 2 ) 0-1 —N(R 8 )R 9 , —(CH 2 ) 0-1 —C(O)N(R 9 )R 9 , —(CH 2 ) 0-1 —C(O)OR 9 , —(CH 2 ) 0-1 —C(O)R 10 , —(CH 2 ) 0-1 —C(O)H, —(CH 2 ) 0-1 —N(R 9 )C(O)R 10 , —(CH 2 ) 0-2 C 3 -C 6 cycloalkyl optionally substituted with 1-3 Z 3 , —(CH 2 ) 0-1 -phenyl optionally substituted with 1-3 Z 5 , or —(CH 2 ) 0-1 -5-6 membered heteroaryl optionally substituted with 1-3 Z 5 ;

T 3 is —(CH 2 ) 0-2 —C(O)N(R 9 )R 9 , —(CH 2 ) 0-2 —N(R 9 )R 9 , —(CH 2 ) 0-2 —C(O)OR 9 , —(CH 2 ) 0-2 —C 3 -C 6 cycloalkyl, —(CH 2 ) 0-2 -5-6 membered heterocycloalkyl, —O-5-6 membered heterocycloalkyl optionally substituted with 4-chloropyridazin-3-one-5-yl, or —(CH 2 ) 0-2 -5-9 membered bridged carbocyclic ring, wherein the —(CH 2 ) 0-2 —C 3 -C 6 cycloalkyl, —(CH 2 ) 0-1 -5-6 membered heterocycloalkyl, or —(CH 2 ) 0-2 -5-9 membered bridged carbocyclic are each optionally substituted with 1-3 Z 5 and 0-1 Z 1 , provided that when T 3 is attached to a heteroatom of G, G cannot be attached to an oxygen or nitrogen atom of T 3 ;

T 4 is —(CH 2 ) 0-1 C(O)OR 9 , —(CH 2 ) 0-1 —N(R 9 )C(O)R 9 , —(CH 2 ) 0-1 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-1 —SO 2 —R 7 , —(CH 2 ) 0-1 —SO 2 N(R 9 )R 9 , —(CH 2 ) 0-1 —N(R 9 )C(O)N(R 9 )R 9 , or N(R a )

each T 5 is independently halogen, hydroxyl, C 1 -C 4 alkyl optionally substituted with 1-3 R b , C 2 -C 4 alkenyl optionally substituted with 1-3 R b , C 2 -C 4 alkynyl optionally substituted with 1-3 R b , CN, C 1 -C 4 cyanoalkyl, C 1 -C 4 alkoxyl optionally substituted with 1-3 R b , or C 1 -C 4 alkoxyC 1 -C 4 alkyl optionally substituted with 1-3 R b , provided that when T 5 is attached to a heteroatom of G, T 5 cannot be halogen, hydroxyl, CN, or C 1 -C 4 alkoxyl optionally substituted with 1-3 R b ;

T 6 is —(CH 2 ) 0-1 —N(R 9 )SO 2 —R 7 , —(CH 2 ) 0-1 —SO 2 —R 7 , —(CH 2 ) 0-1 —SO 2 N(R 9 )R 9 , —(CH 2 ) 0-1 —N(R 9 )SO 2 N(R 9 )R 9 , —(CH 2 ) 0-1 —N(R 9 )C(O)N(R 9 )R 9 , —(CH 2 ) 0-1 —N(R 9 )C(O)R 9 , —(CH 2 ) 0-1 —N(R 9 )C(O)OR 9 , —(CH 2 ) 0-1 —N(R 9 )R 9 , —(CH 2 ) 0-1 —C(O)—N(R 9 )R 9 , —(CH 2 ) 0-1 —C(O)OR 9 , —(CH 2 ) 0-1 —C(O)R 10 , —(CH 2 ) 0-1 —N(R 9 )C(O)R 10 , —N(H)C(H)C═O, —(CH 2 ) 0-1 —C 3 -C 6 cycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-1 -5-6 membered heterocycloalkyl optionally substituted with 1-4 Z 3 , —(CH 2 ) 0-1 -5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , or 4-chloropyridazin-3-one-5-yl, provided that when T 6 is attached to a heteroatom of G, G cannot be attached to an oxygen or nitrogen atom of T 6 ;

R a is H or C 1 -C 4 alkyl;

R b is F, Cl, CN, CF 3 , or hydroxyl, provided that not more than 1 R b can be CF 3 ;

R 2 is H, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 1 -C 4 alkoxyl, C 1 -C 4 haloalkyl, CF 3 , or CN;

R 3 is H, halogen, C 1 -C 4 alkyl, CN, or C 1 -C 4 haloalkyl;

each R 4 is independently halogen, CN, or C 1 -C 4 alkyl optionally substituted with 1-3 halogens;

R 7 is C 1 -C 4 alkyl optionally substituted with 1-3 Z 4 , —C 0 -C 3 alkyl-C 3 -C 6 cycloalkyl optionally substituted with 1-3 Z 3 , —C 0 -C 3 alkyl-phenyl optionally substituted with 1-3 Z 3 , —C 0 -C 1 alkyl-5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , or —C 0 -C 1 alkyl-5-6 membered heterocycloalkyl optionally substituted with 1-3 Z 5 ;

R 8 is H, C 1 -C 4 alkyl optionally substituted with 1-3 Z 4 , C 2 -C 4 alkenyl optionally substituted with 1-3 Z 4 , —C 0 -C 1 alkyl-C 3 -C 6 cycloalkyl optionally substituted with 1-3 Z 3 , —C 0 -C 1 alkyl-phenyl optionally substituted with 1-3 Z 3 , —C 0 -C 1 alkyl-5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , —C 0 -C 1 alkyl-5-6 membered heterocycloalkyl optionally substituted with 1-3 Z 5 , or a 5-9 membered bridged carbocylic ring substituted with 0-3 Ti;

each R 9 is independently H or C 1 -C 4 alkyl optionally substituted with 1-3 Z 4 ;

R 10 is C 1 -C 4 alkyl substituted with 0-3 Z 4 , —C 0 -C 1 alkyl-C 3 -C 6 cycloalkyl optionally substituted with 1-3 Z 3 , —C 0 -C 1 alkyl-phenyl optionally substituted with 1-3 Z 3 , —C 0 -C 1 alkyl-5-6 membered heteroaryl optionally substituted with 1-3 Z 5 , or —C 0 -C 1 alkyl-5-6 membered heterocycloalkyl optionally substituted with 1-3 Z 5 ;

Z 1 is C 1 -C 4 cyanoalkyl, —(CH 2 ) 0-1 —C(O)OR 9 , —(CH 2 ) 0-1 —C(O)—N(R 8 )R 9 , provided that when Z 1 is attached to a heteroatom, then Z 1 is not —C(O)OR 9 ;

each Z 2 is independently hydroxyl, halogen, or CN;

each Z 3 is independently C 1 -C 4 alkyl, halogen, C 1 -C 4 haloalkyl, hydroxyl, C 1 -C 4 hydroxyalkyl, C 1 -C 4 alkoxyl, or CN;

each Z 4 is independently hydroxyl, halogen, C 1 -C 4 alkoxyl, or CN; and

each Z 5 is independently C 1 -C 4 alkyl, C 1 -C 6 haloalkyl, hydroxyl, C 1 -C 4 hydroxyalkyl, halogen, C 1 -C 4 alkoxyl, CN, or C 1 -C 4 cyanoalkyl, provided that when Z 5 is attached to a heteroatom, then Z 5 is not halogen, hydroxyl, C 1 -C 4 alkoxyl, or CN.

6. The compound according to claim 1 , wherein

R 1 is —CH 2 CH 2 OH, —CH 2 CH 2 CH 2 OH, —CH 2 CH(OH)CH 2 OH, or —CH 2 CH(CH 3 )OH;

R 2 is C 1 , Br, CF 3 , or CN; and

E is pyridyl, phenyl, pyrimidinyl, or pyridazinyl.

7. The compound according to claim 6 , wherein R 2 is Cl.

8. A compound according claim 1 having any one of the following formulae:

or a pharmaceutically acceptable salt thereof, wherein R 2 is Cl, Br, CF 3 , or CN.

9. The compound according to claim 1 , wherein T 3 is —CH 2 C(O)N(H)cyclopropyl, —CH 2 C(O)N(H)CH 3 , —CH 2 —COOH, oxetanyl, —(CH 2 ) 0-2 cyclopropyl, —(CH 2 ) 0-2 cyclobutyl, —(CH 2 ) 0-2 -tetrahydropyran, —(CH 2 ) 0-2 -tetrahydrofuran, —(CH 2 ) 0-2 azetidinyl, —(CH 2 ) 0-2 pyrrolidinyl, or —(CH 2 ) 0-2 morpholinyl.

10. The compound according to claim 1 , wherein G is one of the following formulae:

11. The compound according to claim 1 , wherein G is one of the following formulae:

each T 1a is independently F, Cl, or CH 3 ; and

each T 5a is independently F, Cl, or CH 3 .

12. The compound according to claim 11 , wherein G is one of formulae (ae), (af), (ag), (ah), (ai), (aj), (ak), (al), (am), (an), (ao), (ap), or (aq).

13. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 13 , wherein the compound is

15. The compound according to claim 13 , wherein the compound is

16. The compound according to claim 13 , wherein the compound is

17. The compound according to claim 13 , wherein the compound is

18. The compound according to claim 13 , wherein the compound is

19. The compound according to claim 13 , wherein the compound is

20. The compound according to claim 13 , wherein the compound is

21. The compound according to claim 13 , wherein the compound is

22. The compound according to claim 13 , wherein the compound is

23. A pharmaceutical composition comprising a compound of claim 1 , and a pharmaceutically acceptable carrier.

24. A method for treating a subject with a disease or condition mediated by CD73, said method comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer, or a deuterated analog thereof; wherein the disease or condition is a neoplastic disorder, a cancer, an age-related disease, an inflammatory disorder, a cognitive disorder, a neurodegenerative disease, bladder cancer, colorectal cancer, gastric cancer, gall bladder cancer, glioblastoma multiforme, glioma, leukemia, lymphoma, lung cancer, breast cancer, melanoma, multiple myeloma, ovarian cancer, prostate cancer, pancreatic cancer, thyroid cancer, lung fibrosis, liver fibrosis, Alzheimer's disease, multiple sclerosis, or Parkinson's disease.

25. The method of claim 24 , wherein the disease or condition is renal cancer, small-cell lung cancer, non-small cell lung cancer, acute myeloid leukemia, multiple myeloma, diffuse large B-cell lymphoma, breast cancer or prostate cancer.

26. The method according to claim 24 , further comprising administering one or more additional therapeutic agents, wherein the one or more additional therapeutic agents is one or more of i) an alkylating agent; ii) an antibiotic; iii) an antimetabolite; iv) an immunotherapy agent; v) a hormone or hormone antagonist; vi) a taxane; vii) a retinoid; viii) an alkaloid; ix) an antiangiogenic agent; x) a topoisomerase inhibitor; xi) a kinase inhibitor; xii) a targeted signal transduction inhibitor; xiii) a biological response modifier; xiv) an IDO inhibitor; xv) a chemotherapeutic agent; xvi) a Mek inhibitor; xvii) a tyrosine kinase inhibitor; xviii) a c-Kit mutant inhibitor; xix) an EGFR inhibitor; and xx) an epigenetic modulator.

27. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of an alkylating agent selected from adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan.

28. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of an antibiotic selected from bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin.

29. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of an antimetabolite selected from the group consisting of azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate.

30. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of an immunotherapy agent selected from a PD-1 or PD-L1 inhibitor.

31. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a hormone or hormone antagonist selected from the group consisting of enzalutamide, abiraterone, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene.

32. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a taxane selected from DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel.

33. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a retinoid selected from alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin.

34. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of an alkaloid selected from etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine.

35. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of an antiangiogenic agent selected from AE-941, ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide.

36. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a topoisomerase inhibitor selected from amsacrine, edotecarin, exatecan, irinotecan, SN-38, rubitecan, topotecan, and 9-aminocamptothecin.

37. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a kinase inhibitor selected from erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, AEE-788, AG-013736, AMG 706, AMN107, BMS-354825, BMS-599626, UCN-01, vemurafenib, dabrafenib, trametinib, cobimetinib selumetinib and vatalanib.

38. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a targeted signal transduction inhibitor selected from bortezomib, geldanamycin, and rapamycin.

39. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a biological response modifier selected from imiquimod, interferon-α and interleukin-2.

40. The method according to claim 26 , wherein the one or more additional therapeutic agents is one or more of a chemotherapeutic agent selected from 3-amino-2-carboxyaldehyde thiosemicarbazone, altrasentan, aminoglutethimide, anagrelide, asparaginase, bryostatin-1, cilengitide, elesclomol, eribulin mesylate, ixabepilone, lonidamine, masoprocol, mitoguanazone, oblimersen, sulindac, testolactone, tiazofurin, a mTOR inhibitor, a PI3K inhibitor, a Cdk4 inhibitor, an Akt inhibitor, a Hsp90 inhibitor, a farnesyltransferase inhibitor or an aromatase inhibitor.